---
title: "QuidelOrtho (QDEL): Evaluating Valuation After Q3 Earnings Miss, Guidance Cut, and Operational Hurdles"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265446765.md"
description: "QuidelOrtho (QDEL) reported disappointing Q3 earnings, with declining revenues and a significant net loss, leading to a reduced full-year outlook. Despite a recent 11% share price rally, the stock has seen a 1-year total return of -46.8%. Analysts value the stock at $37.67, indicating it is undervalued at its current price of $21.89. Operational improvements may enhance margins, but ongoing revenue declines and product discontinuations pose risks to recovery. Investors are encouraged to explore broader opportunities beyond healthcare."
datetime: "2025-11-12T06:00:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265446765.md)
  - [en](https://longbridge.com/en/news/265446765.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265446765.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265446765.md) | [繁體中文](https://longbridge.com/zh-HK/news/265446765.md)


# QuidelOrtho (QDEL): Evaluating Valuation After Q3 Earnings Miss, Guidance Cut, and Operational Hurdles

QuidelOrtho (QDEL) just released its third quarter earnings, highlighting a mix of declining revenues, a large net loss, and a lowered full-year earnings outlook. The company is also facing several operational headwinds.

See our latest analysis for QuidelOrtho.

Despite a recent rally that saw QuidelOrtho's share price jump nearly 11% in a single day, the broader trend has been decidedly negative, with a 1-year total shareholder return of -46.8% and a year-to-date share price return of -51.4%. While new FDA approvals and operational initiatives hint at long-term resilience, momentum is still fading as the company works through ongoing challenges.

If earnings volatility has you rethinking your next move, it might be time to discover opportunities beyond healthcare and see which high potential companies stand out with fast growing stocks with high insider ownership

With QuidelOrtho now trading at a substantial discount to analyst price targets after significant losses and a lowered outlook, investors are left wondering whether there is real value on the table or if the market is simply bracing for more pain to come.

## Most Popular Narrative: 41.9% Undervalued

With the most widely followed narrative placing QuidelOrtho’s fair value at $37.67 compared to a last close of $21.89, the market is currently offering deep pessimism relative to future expectations. This sets up a stark valuation gap and raises major questions about the numbers driving this difference.

> _Continued operational improvements, such as indirect procurement cost reductions, manufacturing site consolidation, and successful ERP system integration, are yielding significant margin and EBITDA gains. Incremental savings are expected to directly benefit net margins and EPS into 2026 and beyond._

Read the complete narrative.

Curious what’s powering this premium valuation? The narrative hinges on assumptions about sharply rising margins and the impact of massive cost savings yet to reach the bottom line. See what controversial forecasts and future profit multiples are fueling the bold fair value; they might catch you off guard.

**Result: Fair Value of $37.67 (UNDERVALUED)**

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing COVID-related revenue declines and discontinued product lines could undermine QuidelOrtho's recovery narrative, particularly if no new growth drivers emerge soon.

Find out about the key risks to this QuidelOrtho narrative.

## Build Your Own QuidelOrtho Narrative

If you want to dig into the numbers and interpret the story differently, you can build a personalized narrative in just a few minutes, your way with Do it your way.

A great starting point for your QuidelOrtho research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

## Looking for More Investment Ideas?

There is a world of opportunity beyond a single stock, and you can take charge right now by targeting the themes and trends that matter most to your goals. Make sure you don't miss out on these handpicked opportunities available on Simply Wall Street:

-   Lock in potential passive income streams when you analyze these 15 dividend stocks with yields \> 3% with yields above 3% to boost your portfolio's cash flow.
-   Embrace innovation and future growth by investigating the latest winners among these 26 AI penny stocks, where artificial intelligence is powering rapid change.
-   Capitalize on market mispricing by reviewing these 872 undervalued stocks based on cash flows, highlighting companies trading below their intrinsic worth right now.

_This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

### Related Stocks

- [QuidelOrtho Corporation (QDEL.US)](https://longbridge.com/en/quote/QDEL.US.md)

## Related News & Research

- [QuidelOrtho (QDEL) Gets a Buy from Craig-Hallum](https://longbridge.com/en/news/264061502.md)
- [A Look At Webster Financial (WBS) Valuation After Mixed Recent Shareholder Returns](https://longbridge.com/en/news/280962299.md)
- [Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields](https://longbridge.com/en/news/281183048.md)
- [11:35 ETMediaspace Health Launches to Deliver Innovative Media Strategies for Agencies, Pharma and Healthcare Brands](https://longbridge.com/en/news/281213630.md)
- [Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/280883162.md)